ABOUT KATI

To decipher the mechanism of immune activation and concentrate on development of novel drugs, Dr. Enxiu Wang, a former core member of Dr. Carl June team, founded Nanjing KATI, an innovative cell drug company. The University of Pennsylvania is the well-known cradle of CAR-T drug development, and Dr. Carl June is the pioneer of CAR-T immunotherapy. Nanjing KATI adheres to its pioneering and pragmatic style and is committed to the development and application of independent innovative drugs. Nanjing KATI focuses on the four product matrices of “Identification, Activation, Carrier, and Technology" in solid tumor cell therapy.